ShenZhen Geno-immune Medical Institute (GIMI) was established in 2015 and funded by the Municipal Government of Shenzhen. GIMI faculty and team focus on translational research of medicine, particularly cell-based immunotherapies and gene therapies.
Headed by Professor Dr. Lung-Ji Chang, GIMI also retains several international leading scientists with pioneering expertise in molecular biology, medicine, translational trials, and biomedical innovation.
GIMI has currently accumulated many cheerful results by its 4th generation CAR-T immunotherapy in treatment of late stage cancers. So far, more than 1000 cancer patients (both domestic and overseas) have been treated through GIMI with the advanced CAR-T technologies.